<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01456364</url>
  </required_header>
  <id_info>
    <org_study_id>GE-DHM A01811</org_study_id>
    <nct_id>NCT01456364</nct_id>
  </id_info>
  <brief_title>Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing</brief_title>
  <acronym>ISAR ADAPT PF</acronym>
  <official_title>Prospective, Randomized Study of the Platelet Inhibitory Efficacy of Ticagrelor Versus Prasugrel in Clopidogrel Low Responders After Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clopidogrel low response is associated with a significantly higher risk for ischemic
      complications after percutaneous coronary intervention. Ticagrelor and prasugrel are more
      potent platelet inhibitory drugs and both have been shown to significantly reduce ischemic
      events as compared to clopidogrel. No direct comparison between ticagrelor and prasugrel in
      terms of their antiplatelet efficacy exists. The aim of this study is to assess the
      antiplatelet treatment efficacy of ticagrelor versus prasugrel over time in confirmed
      clopidogrel low responders undergoing percutaneous coronary intervention.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ADP-induced platelet aggregation after randomized treatment with ticagrelor or prasugrel</measure>
    <time_frame>Day 2 post randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of low responders in ticagrelor or prasugrel group</measure>
    <time_frame>Day 2 post randomization</time_frame>
    <description>Low platelet response is defined as platelet aggregation values &gt;=468 AU*min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of enhanced responders in ticagrelor or prasugrel group</measure>
    <time_frame>Day 2 post randomization</time_frame>
    <description>Enhanced platelet response is defined as platelet aggregation values &lt;= 188 AU*min</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A loading dose of 180 mg of ticagrelor is administered followed by 90 mg maintenance doses twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A prasugrel loading dose of 60 mg is administered followed by a 10 mg per day maintenance dose for patients &lt; 75 years or a 5 mg maintenance dose per day for patients &gt;= 75 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>A loading dose of 180 mg of ticagrelor is administered followed by 90 mg maintenance doses twice daily</description>
    <arm_group_label>Ticagrelor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>A prasugrel loading dose of 60 mg is administered followed by a 10 mg per day maintenance dose for patients &lt; 75 years or a 5 mg maintenance dose per day for patients &gt;= 75 years</description>
    <arm_group_label>Prasugrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  successful PCI

          -  600 mg clopidogrel pretreatment

          -  clopidogrel low response assessed with electrode aggregometry (&gt;= 486 AU*min)

          -  written informed consent

        Exclusion Criteria:

          -  Contraindications or allergies against study drugs

          -  Anemia

          -  Any surgery &lt; 6 weeks

          -  Increased bleeding risk

          -  Oral anticoagulation

          -  platelet count &lt; 100.000/µl

          -  Prior history of stroke or pathologic intracranial findings

          -  GPIIb/IIIa antagonists &lt; 10 days or periprocedural

          -  Age &gt; 80 years, &lt; 18 years

          -  Body weight &lt; 60 kg

          -  Cardiogenic shock

          -  Increased risk of bradycardia

          -  Moderate liver disease

          -  Kidney dialysis

          -  Intake of CYP 3A4 inhibitors

          -  Pregnancy or lactation

          -  Missing pregnancy test for women capable of bearing children
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katharina Mayer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum München</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Orban, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum der Ludwig-Maximilian-Universität München, Campus Großhadern</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Aradi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart Center Balatonfüred, Dept. of Cardiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katharina Mayer, MD</last_name>
    <phone>+49-89-1218-2020</phone>
    <email>mayer.katharina@dhm.mhn.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabell Bernlochner, MD</last_name>
    <phone>+49-89-1218-0</phone>
    <email>isabell.bernlochner@gmx.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Deutsches Herzzentrum</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katharina Mayer, MD</last_name>
      <phone>+49-89-1218-2020</phone>
      <email>mayer.katharina@dhm.mhn.de</email>
    </contact>
    <contact_backup>
      <last_name>Isabell Bernlochner, MD</last_name>
      <phone>+49-89-4140-0</phone>
      <email>isabell.bernlochner@gmx.de</email>
    </contact_backup>
    <investigator>
      <last_name>Katharina Mayer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabell Bernlochner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Ludwig-Maximilians-Universität München</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Orban, MD</last_name>
      <phone>+49 89 7095 2371</phone>
      <email>martin.Orban@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Dirk Sibbing, MD</last_name>
      <phone>+49 89 5160 2215</phone>
      <email>Dirk.Sibbing@med.uni-muenchen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Martin Orban, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dirk Sibbing, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heart Center Balatonfüred, Dept. of Cardiology</name>
      <address>
        <city>Balatonfüred</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Aradi, MD</last_name>
      <phone>+36302355639</phone>
      <email>daniel_aradi@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Aradi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jozsef Faluközy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
  </location_countries>
  <reference>
    <citation>Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schömig A, Kastrati A, von Beckerath N. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol. 2009 Mar 10;53(10):849-56. doi: 10.1016/j.jacc.2008.11.030.</citation>
    <PMID>19264241</PMID>
  </reference>
  <reference>
    <citation>Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007 Nov 15;357(20):2001-15. Epub 2007 Nov 4.</citation>
    <PMID>17982182</PMID>
  </reference>
  <reference>
    <citation>Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10;361(11):1045-57. doi: 10.1056/NEJMoa0904327. Epub 2009 Aug 30.</citation>
    <PMID>19717846</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2011</study_first_submitted>
  <study_first_submitted_qc>October 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2011</study_first_posted>
  <last_update_submitted>October 31, 2013</last_update_submitted>
  <last_update_submitted_qc>October 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>clopidogrel low response</keyword>
  <keyword>ticagrelor</keyword>
  <keyword>prasugrel</keyword>
  <keyword>platelet aggregation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

